share_log

Goldman Sachs Initiates Coverage On Tarsus Pharmaceuticals With Neutral Rating, Announces Price Target of $19

Goldman Sachs Initiates Coverage On Tarsus Pharmaceuticals With Neutral Rating, Announces Price Target of $19

高盛以中性評級啓動對塔蘇斯製藥的報道,宣佈目標股價爲19美元
Benzinga ·  2023/11/20 04:43

Goldman Sachs analyst Andrea Tan initiates coverage on Tarsus Pharmaceuticals (NASDAQ:TARS) with a Neutral rating and announces Price Target of $19.

高盛分析師安德里亞·譚以中性評級開始對塔蘇斯製藥(納斯達克股票代碼:TARS)進行報道,並宣佈目標股價爲19美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論